Sweden: IRRAS to raise SKr217m in rights issue

Kleanthis Xanthopoulos, president and CEO, IRRAS

Swedish medtech company IRRAS is to raise SKr217m (US$22.3m) in a fully underwritten rights issue to help commercialise its products. It is selling 37.5 million shares at SKr5.80 per share before 9 April. IRRAS has received subscription undertakings for 25% of the rights issue from existing shareholders. The company’s larger shareholders Lexington Holding Assets and…

You must be a HMI Subscriber to view this content.

Subscribe Now »